Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Graphical abstract

Highlights

- Reduced B.1.351 neutralization by mAbs and sera induced by early SARS-CoV-2 isolates
- B.1.351 neutralization titer reduced 8- to 9-fold for Pfizer and AstraZeneca vaccinees
- E484K, K417N, and N501Y cause widespread escape from mAbs
- NTD deletion in B.1.351 abrogates neutralization by a potent neutralizing human mAb

Authors

Daming Zhou, Wanwisa Dejnirattisai, Piyada Supasa, ..., Jingshan Ren, David I. Stuart, Gavin R. Screaton

Correspondence

jmongkol@well.ox.ac.uk (J.M.), ren@strubi.ox.ac.uk (J.R.), dave.stuart@diamond.ac.uk (D.I.S.), gavin.screaton@medsci.ox.ac.uk (G.R.S.)

In brief

Structure-function analysis of the SARS-CoV-2 variant B.1.351 using serum samples from convalescent and vaccinated individuals reveals how mutations in the viral spike protein result in tighter binding to the receptor ACE2 and allow escape from monoclonal antibody neutralization.
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Daming Zhou,1,21 Wanwisa Dejnirattisai,2,21 Piyada Supasa,2,21 Chang Liu,2,3,21 Alexander J. Mentzer,2,4,21 Helen M. Ginn,20 Yuguang Zhao,1 Helen M.E. Duyvesteyn,1 Aekkachai Tuekprakhon,2 Rungtiwa Nutalai,2 Beibei Wang,2 Guido C. Paesen,1 Cesar Lopez-Camacho,2 Jose Slon-Campos,2 Bassam Hallis,5 Naomi Coombes,5 Kevin Bewley,5 Sue Charlton,1 Thomas S. Walter,2 Donal Skelly,1,4,7 Sheila F. Lumley,1,4,7 Christina Dold,5,12 Robert Levin,1 Tao Dong,3,12 Andrew J. Pollard,2,10 Julian C. Knight,2,3,4,12 Derrick Crook,8 Teresa Lambe,11 Elizabeth Clutterbuck,11 Sagida Bibi,11 Amy Flaxman,13 Mustapha Bittaye,13 Sandra Belij-Rammerstorfer,13 Sarah Gilbert,13 William James,14 Miles W. Carroll,2,5 Paul Kleneman,1,6,9,15 Eleanor Barnes,4,6,9,15 Susanna J. Dunachie,4,6,9,16,17 Elizabeth E. Fry,1 Juthathip Mongkolsapaya,2,3,18,* Jingshan Ren,1,* David I. Stuart,1,3,19,20,22,* and Gavin R. Screaton2,3,*

1Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK
2Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
3Chinese Academy of Medical Science (CAMS), Oxford Institute (COI), University of Oxford, Oxford, UK
4Oxford University Hospitals NHS Foundation Trust, Oxford, UK
5National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK
6Peter Medawar Building for Pathogen Research, Oxford, UK
7Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
8Nuffield Department of Medicine, University of Oxford, Oxford, UK
9NIHR Oxford Biomedical Research Centre, Oxford, UK
10Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK
11Worthing Hospital, Worthing, UK
12MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
13Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK
14Sir William Dunn School of Pathology University of Oxford, Oxford, UK
15Translational Gastroenterology Unit, University of Oxford, Oxford, UK
16Centre For Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
17Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand
18Siriraj Center of Research Excellence in Dengue & Emerging Pathogens, Dean Office for Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
19Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK
20Instruct-ERIC, Oxford House, Parkway Court, John Smith Drive, Oxford, UK
21These authors contributed equally
22Lead contact
*Correspondence: jmongkol@well.ox.ac.uk (J.M.), ren@strubi.ox.ac.uk (J.R.), dave.stuart@diamond.ac.uk (D.I.S.), gavin.screaton@medsci.ox.ac.uk (G.R.S.)
https://doi.org/10.1016/j.cell.2021.02.037

SUMMARY
The race to produce vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began when the first sequence was published, and this forms the basis for vaccines currently deployed globally. Independent lineages of SARS-CoV-2 have recently been reported: UK, B.1.1.7; South Africa, B.1.351; and Brazil, P.1. These variants have multiple changes in the immunodominant spike protein that facilitates viral cell entry via the angiotensin-converting enzyme-2 (ACE2) receptor. Mutations in the receptor recognition site on the spike are of great concern for their potential for immune escape. Here, we describe a structure-function analysis of B.1.351 using a large cohort of convalescent and vaccinee serum samples. The receptor-binding domain mutations provide tighter ACE2 binding and widespread escape from monoclonal antibody neutralization largely driven by E484K, although K417N and N501Y act together against some important antibody classes. In a number of cases, it would appear that convalescent and some vaccine serum offers limited protection against this variant.

INTRODUCTION
Reports of a severe acute respiratory syndrome (SARS) emerged in December 2019, with rapidly increasing cases and deaths in Wuhan, China. The virus, SARS-coronavirus 2 (CoV-2) was rapidly identified, with the sequence published in January 2020 (Lu et al., 2020), and the disease it caused subsequently named coronavirus disease 2019 (COVID-19). SARS-CoV-2 has been
estimated to have infected at least 118 million people, with 2.6 million deaths worldwide (https://www.worldometers.info/coronavirus).

An unprecedented global scientific effort has been led by multiple pharmaceutical companies and academic laboratories to produce vaccines against SARS-CoV-2 (https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines), seen by many as the only realistic way to release populations from the harsh social isolation measures being implemented in many countries and the consequential severe economic disruption (Keogh-Brown et al., 2020). Many vaccine candidates have been developed, all aiming to generate antibody (and T cell) responses against the spike protein of SARS-CoV-2. These have been developed using spike sequences derived from the early Wuhan strain and include recombinant protein, inactivated virus, RNA, and virally vectored platforms (Krammer, 2020). With accelerated trials, the first efficacy results were delivered around 10 months following the first publication of the sequence of SARS-CoV-2 (Polack et al., 2020; Voysey et al., 2021a; Baden et al., 2021).

Impressive results have now been reported from a variety of manufacturers: Novavax-recombinant spike and Janssen-adenoviral-vectored vaccines have recently reported good efficacy (https://www.novavax.com/sites/default/files/2021-02/20210202-NYAS-Novavax-Final.pdf; https://www.medscape.com/viewarticle/944933), while Moderna-RNA, Pfizer/BioNTech-RNA, and Oxford-AstraZeneca-chimp adenoviral-vectored vaccines have already received emergency use authorization (EUA) in a number of countries and will be deployed at massive scale in 2021.

In the past few weeks, there have been reports of variant strains of SARS-CoV-2 emerging in different parts of the world. B.1.1.7 was first identified in the UK from a sample obtained in October 2020, B.1.351 was identified in October 2020 in South Africa, and P.1 was identified in Brazil in December 2020 (https://www.cogconsortium.uk/wp-content/uploads/2021/01/Report-2_COG-UK_SARS-CoV-2-Mutations.pdf). These variant strains have picked up multiple changes (deletions and substitutions) in the spike protein: 9 in B.1.1.7, 10 in B.1.351, and 12 in P.1, compared with the Wuhan sequence. Of greatest concern are mutations in the receptor-binding domain (RBD) of the spike protein. The RBD is contained in the S1 subunit of spike and is responsible for interacting with the SARS-CoV-2 cellular receptor angiotensin-converting enzyme-2 (ACE2) (Hoffmann et al., 2020). The ACE2 interaction surface of the RBD is a relatively small 25-amino-acid patch at the tip of the RBD (Shang et al., 2020), and because of its crucial role in viral attachment, it is also the site for binding of many potent neutralizing antibodies (Cerutti et al., 2021). Blocking RBD-ACE2 interaction is thought to play a major role in natural and vaccine-induced protection from SARS-CoV-2 infection. A number of such monoclonal antibodies (mAbs) have been combined into cocktails that are in advanced trials for treatment and prophylaxis of SARS-CoV-2 (Yang et al., 2020).

The ACE2-binding surface is to some extent the Achilles heel of the virus as it can be blocked by some neutralizing antibodies; however, since it is so small, it also threatens immune escape, as small changes can throw off neutralizing antibodies, thereby reducing the ability of natural or vaccine-acquired immunity to contain viral replication. Selective pressure for changes in the ACE2 interaction surface can thus have two entirely separate drivers. First, as SARS-CoV-2 has recently crossed a zoonotic barrier, it may be expected that evolution of the ACE2 interaction surface may occur to increase affinity to ACE2 and thereby increase viral transmissibility. And second, conversely, changes to the ACE2 interaction surface may also reduce the protection afforded by previous infection or vaccination, potentially leading to escape from pre-existing immunity induced by natural infection or vaccines.

All three recently identified variant SARS-CoV-2 strains have acquired mutations in the ACE2 interaction surface of the RBD: N501Y in B.1.1.7; K417N, E484K, and N501Y in B.1.351; and K417T, E484K, and N501Y in P.1. All three variants may lead to increased transmissibility, with good evidence for this with B.1.1.7 in the UK. These have rapidly expanded to become the dominant strains in the regions where they were first identified and global spread, particularly for B.1.1.7 and B.1.351, is causing considerable concern.

Here, we examine neutralization of a B.1.351 viral isolate and compare this to neutralization of Victoria (SARS-CoV-2/human/AUS/VIC01/2020), an early Wuhan-related isolate. Neutralization assays are performed on a large panel of mAbs (Dejnirattisai et al., 2021), convalescent sera from early in the pandemic, sera from patients suffering from B.1.1.7, and finally sera from recipients of the Oxford-AstraZenica and Pfizer-BioNTech vaccines. There is evidence of widespread escape from mAbs, for which we provide a structural and biophysical description. Neutralization of B.1.351 by sera from naturally infected or vaccinated individuals is significantly reduced, leading in some cases to a complete inability to neutralize B.1.351 virus.

RESULTS

Mutational changes in B.1.351

A number of isolates of B.1.351 have been described, all of which have the key mutations K417N, E484K, and N501Y in the RBD. Tegally et al. (2021) reported an isolate containing 10 changes relative to the Wuhan sequence: L18F, D80A, D215G, L242-244 deleted, R246l, K417N, E484K, N501Y, D614G, and A701V. Sequencing of the strain used in this report, from a case in the UK, shows only 8 changes and lacks L18F and R246l compared with the Tegally et al. (2021) isolate. Coronaviruses genome sequences were analyzed in both the UK, acquired from the COVID-19 Genomics UK (COG-UK) database (Tatusov et al., 2000), and South Africa, acquired from the Global Initiative on Sharing Avian Influenza Data (GISAID) (https://www.gisaid.org). It appears that B.1.1.7 and B.1.351 quickly became overwhelmingly dominant in the UK and South Africa, respectively. In the evolution of both the B.1.1.7 variant in the UK and the B.1.351 variant in South Africa, a substantial population of N-terminal domain (NTD)-deletion-only mutants (Δ69–70 in B.1.1.7 and Δ242–244 in B.1.1.153), and N501Y-only mutants were observed in both countries preceding the rising dominance of strains harboring both deletions and 501Y (Figures 1A and 1B). Counts of both “single-mutant” variants have since waned. The characteristic mutations for B.1.351 as found in South Africa
are shown in Figures 1C–1E. In addition, as of February 2, 2021, in the COG-UK database, 21 of the B.1.1.7 sequences were observed to have independently acquired the 484K (but not the 417N) mutation found in the B.1.351 variant, and 90 sequences display these mutations in the background of B.1.351 (as defined by bearing the characteristic Δ242–244 NTD deletion).

Neutralization of B.1.351 by convalescent plasma

We collected plasma from a cohort of infected patients during the first wave of SARS-CoV-2 infection in the UK. Samples were collected from convalescent cases 4–9 weeks following infection in June 2020, before the emergence of B.1.1.7 (Dejnirattisai et al., 2021). We have also included a recent collection of plasma from patients infected with B.1.1.7 (Supasa et al., 2021).

Neutralization titers against Victoria, an early Wuhan-related strain of SARS-CoV-2 (Caly et al., 2020; Seemann et al., 2020), were compared with B.1.351 using a focus reduction neutralization test (FRNT). For the early convalescent samples (n = 34), neutralization titers against B.1.351 were, on average, 13.3-fold reduced compared with Victoria (p < 0.0001) (Figure 2A; Table S1A). A few convalescent samples, e.g., 4, 6, and 15 retained good neutralization of B.1.351, but for most, titers were considerably reduced. Significantly, 18 of 34 samples failed to reach 50% neutralization at a plasma dilution of 1:20, with a number showing a near total reduction of neutralization activity. Overall, in the 34 convalescent plasma samples there was a 13.3-fold (geometric mean) reduction in neutralization titer between Victoria and B.1.351 (p < 0.0001) (Figure 2C).

Neutralization was also performed using plasma recently collected, at different time points, from patients suffering from B.1.1.7 (n = 13). All of these cases had S-gene knockout on diagnostic PCR (Thermo Fisher Scientific TaqPath, characteristic of B.1.1.7), and 11 had viral sequencing confirming B.1.1.7 (Figure 2B; Table S1B). Neutralization titers were low at early time points for both Victoria and B.1.351, but one case (B.1.1.7 P4), a sample taken 1 day following admission to hospital, showed a very high titer against Victoria (1:136,884) and B.1.351 (1:81,493). We speculate this may represent a reinfection with B.1.1.7. Overall, there was a 3.1-fold (geometric mean) reduction in titers between Victoria and B.1.351 in sera from patients infected with B.1.1.7 (Figure 2D).

Neutralization of B.1.351 by vaccinee serum

We next measured neutralization of Victoria and B.1.351 using vaccine serum obtained from individuals vaccinated with either the Pfizer-BioNTech vaccine BNT162b2 or the Oxford-AstraZeneca AZD1222 vaccine. For Pfizer-BioNTech, vaccinated serum...
was obtained from healthcare workers (n = 25) 4–17 days following the second dose of vaccine, administered 3 weeks after the first dose (Figure 3A; Table S2). For the AstraZeneca vaccine, samples (n = 25) were obtained 14 or 28 days following the second vaccine dose, with a dosing interval of 8–14 weeks (Figure 3B; Table S2). For the Pfizer-BioNTech vaccine serum, geometric mean B.1.351 titers were 9-fold lower than for Victoria (p < 0.0001) (Figure 3D; Table S2). Plasma taken pre-first dose of the Oxford-AstraZeneca vaccine showed, as expected, minimal or absent neutralization of Victoria or B.1.351 viruses (Figure S1).

The Pfizer-BioNTech vaccine serum induced 3.6-fold higher neutralization titers against the Victoria strain than the Oxford-AstraZeneca vaccine (p < 0.0001). Although the overall reduction of titers was quite similar, 7.6-fold versus 9-fold, respectively, because the AstraZeneca titers started from a lower base more of the samples failed to reach 50% FRNT titers against B.1.351 (9/25) than for the Pfizer vaccine (2/25), although one of these (Pfizer 2) also showed low neutralizing titers to the Victoria virus.

Neutralization of B.1.351 by a large panel of mAbs
We have produced and characterized a pool of 377 human mAbs directed to the spike protein, raised from convalescent samples obtained from patients infected during the first wave of SARS-CoV-2 in the UK before June 2020; therefore, they were not induced in response to infection with recent SARS-CoV-2 strains (Dejnirattisai et al., 2021). We selected the 20 most potent mAbs (FRNT_{50} titers < 100 ng/mL, 19 anti-RBD and 1 anti-NTD) and performed neutralization assays against Victoria and B.1.351 strains (Figure 4; Table S3A).

The effects on mAb neutralization were severe, 14 of 20 antibodies had >10-fold fall in neutralization titers, with most of these showing a complete knockout of activity. This is in line with the key roles of K417, E484, and N501, in particular E484, in antibody recognition of the ACE2 interaction surface of the RBD described below and in Figures 5A–5G.

Interestingly, the single potent NTD-binding antibody included in these analyses, mAb 159, also showed a complete knockout of activity against B.1.351, which includes deletion of amino acids 242–244 in the NTD, part of the epitope for mAb 159. As can be seen from Figures 5H and 5I, the RBD loop 246–253 interacts with the heavy chain (HC) of mAb 159 and also that of 4A8, another potent neutralizing NTD binder with a structure reported (Chi et al., 2020). The 242–244 deletion will undoubtedly alter the presentation of this loop, compromising binding to these mAbs. Binding at this so-called “supersite” has been reported as of potential therapeutic relevance (McCallum et al., 2021). The B.1.1.7, B.1.351, and P.1 lineages have all converged with either deletions or systematic changes in the NTD. Although P.1 does not harbor NTD deletions, the changes L18F, T20N, and P26S (Faria et al., 2021) would be expected to impact markedly on binding at the NTD epitope. Since these convergent features may have arisen prior to strong selective pressure from antibody responses, it seems likely there is an underlying biological driver still to be discovered, like the increased receptor binding and potential increased transmissibility imparted by the RBD mutations, which may cause this epitope to be extremely susceptible to mutation and escape from antibody binding.

Neutralization of B.1.351 by mAbs in late-stage clinical trials
A number of mAbs are in late-stage clinical trials as therapy or prophylaxis against SARS-CoV-2 (Ku et al., 2021; Baum et al., 2020). Regeneron and AstraZeneca use cocktails of 2 mAbs to give resistance to mutational escape of viruses (Kemp et al., 2021). We performed neutralization assays with the Regeneron pair REGN10933 and REGN10987 and the AstraZeneca pair AZD106 and AZD8895 (Figure 4B; Table S3B). The neutralization of REGN10987 was unaffected by B.1.351, while REGN10933 was severely impaired (773-fold) (Figure 4B; Table S2). Neutralization by the AZ pair of antibodies was little affected on B.1.351 compared with Victoria.

Understanding the abrogation of neutralization: ACE2 binding to B.1.351 RBD
The triple mutation K417N, E484R, and N501Y is characteristic of the B.1.351 RBD. These residues are situated within the ACE2 footprint (Figure 1E), and in vitro evolution to optimize the affinity for ACE2 has suggested that they confer higher affinity for the receptor (Starr et al., 2020; Zahradnik et al., 2021). To investigate this effect, we measured the kinetics of binding of soluble ACE2 to recombinant RBD by biosensor interferometry (BLI) (Figures 6A and 6B). As expected, the affinity for B.1.351 RBD is high; in fact, it is 19-fold higher than for the Victoria RBD and 2.7-fold higher than for B.1.1.7 (Dejnirattisai et al., 2021; Supasa et al., 2021). The K_{D} is 4.0 nM, K_{on} is 4.78E4/Ms, and K_{off} is 1.93E–4/s; thus, the off-rate is approximately 1.5 h. This will further exacerbate the decline in potency observed in neutralization assays, since antibodies of lower affinity will struggle to compete with ACE2 unless they have a very slow off-rate or show an avidity effect to block attachment. Thus, while all of our set of potent RBD binders have an affinity higher than that between ACE2 and Victoria or B.1.1.7 RBD (K_{D}s of 75.1 and 10.7 nM, respectively), five of the 19 have lower or equal affinity than for ACE2 and B.1.351 RBD. A small further...
increase in affinity (e.g., 2-fold) would beat almost all the antibodies (Dejnirattisai et al., 2021; Supasa et al., 2021).

The influence of RBD mutations on mAb affinity
To understand the order of magnitude of the abrogation in neutralization of more than two-thirds of the 19 potent mAbs that bind the RBD, we measured the KDs for binding to recombinant RBD by BLI (Figures 6C and 6D; Table S3). The results are stark: whereas for the antigen binding fragments (Fabs) tested against Victoria, 17 had KDs below 4 nM (the affinity of ACE2 for B.1.351) against B.1.351, this reduced to 4 (or 2 if the engineered light-chain [LC] versions of 253 are removed (Dejnirattisai et al., 2021)), with 7 Fabs failing to achieve near-micromolar affinity. These results broadly follow the neutralization results (compare panels C and D of Figure 6; see Table S3), suggesting that the observed pattern of effects on neutralization is largely due to the amino acid substitutions in the RBD, that is, K417N, E484K, and N501Y.

The structural basis for loss of mAb binding
We attempt to understand the basis of these effects in the context of an anatomical description of the RBD. In terms of a human torso, we have defined four almost contiguous structural epitopes: left shoulder, neck, right shoulder, and right flank, with a separate left flank epitope (Dejnirattisai et al., 2021) (Figure 6E). In this context, the ACE2-binding site extends across the neck and both shoulders. N501Y is on the right shoulder. K417N at the back of the neck, and E484R on the left shoulder. Although the three mutations are nominally in different epitopes, the overlapping nature of these epitopes means that the residues are sufficiently close so that more than one might directly affect the binding of any one antibody. In addition, there may be allosteric effects (the structural equivalent of epistasis in genetics) whereby effects may extend over some distance. Despite these caveats, the majority of the effects observed are directly explicable by reference to prior structural knowledge.

The effect of N501Y and K417N on mAb binding
Many of the reported Fab/SARS-CoV-2 RBD complexes are for antibodies that use the public immunoglobulin HC variable (IGHV) region IGHV3-53 ((Dejnirattisai et al., 2021; Yuan et al., 2020), and these are well represented in our set by five anti-bodies that are potent against the Victoria virus. This mAb approaches the binding site from the front of the neck of the RBD, with very similar approach orientations also shared by the IGHV3-66 Fabs. The majority of these make direct contacts to K417 and N501, but none of them contact E484. The rather short HC complementarity-determining regions-3 (CDR3s) of these Fabs are usually positioned directly above K417 (Dejnirattisai et al., 2021), making hydrogen bonds or salt bridges as well as hydrophobic interactions, while N501 interacts with the LC CDR1 loop (Figure 5) (Supasa et al., 2021). However, mAb 150 is a little different, forming both a salt bridge between K417 and the LC CDR3 D92 and a hydrogen bond between N501 and S30 in the LC CDR1 (Figure 5B), whereas 158 is more typical, making a hydrogen bond from the carbonyl oxygen of G100 of the HC CDR3 and K417 and hydrophobic contacts from S30 of the LC CDR1 to N501. We would therefore expect that the combined effects of the K417N and N501Y mutations would severely compromise the binding of most IGHV3-53 and IGHV3-66 class mAbs. However, one member of this class, 222, is unaffected by either the B.1.1.7 (Supasa et al., 2021) or the B.1.351 variant. Unfortunately, to date we have been unable to obtain a structure of the 222 Fab with RBD or spike. However, we have previously noted that p2c-2f11 Fab (PDB: 7CDI [Wajnberg et al., 2020]) whose LC is most similar in sequence, and has the same CDR-L1, L2, and L3 lengths, to mAb 222 does not make any contact with N501 (Supasa et al., 2021).

By closely examining the structures of the IGHV3-53 and IGHV3-66 Fab and RBD complexes, we found that Fab CB6 (PDB: 7C01 [Shi et al., 2020]) has the same CDR-H1-3 lengths, to mAb 222 does not make any contact with Y52, compensating for the loss of contact to D104 (Figures 5F and 5G). In 222, Y33 and Y52 are conserved and D104 of the HC. Changing the K to N at 417 in this complex structure and selecting one of the favorable side-chain rotamers shows that N417 could make hydrogen bonds to both Y33 and Y52, compensating for the loss of contact to D104 (Figures 5F and 5G). In 222, Y33 and Y52 are conserved and D104 is replaced by an N. We speculate that the interaction of 222 with K417 might be similar to CB6, explaining its resistance to the B.1.351 variant.

The effects of the E484K mutation
Fab 88 binds RBD at the back of the left shoulder, residues G104 and K108 of the HC CDR3 contact E484, and the LC CDR2 makes extensive hydrophobic interactions and a main-chain hydrogen bond from Y51 and a salt bridge from D53 to K417 (Figure 5A). The change of charge at E484 from negative to positive and shortening of the residue 417 side chain from K to N would be expected to abolish all these interactions, explaining the several hundred-fold loss in KD. mAb 384 is one of the most potent neutralizing mAbs we have found against the Victoria virus. This mAb approaches the binding site from the front of the left shoulder, burying 82% of the solvent-accessible area of E484 by hydrogen bonding with Y50, T57, and Y59 as well as making a salt bridge with R52 of the LC CDR2 (Figure 5D),
A

| 40 | 55 | 58 | 88 |
|----|----|----|----|

| 132 | 150 | 158 | 159 |
|-----|-----|-----|-----|

| 165 | 170 | 175 | 222 |
|-----|-----|-----|-----|

| 253 | 269 | 278 | 281 |
|-----|-----|-----|-----|

| 316 | 318 | 384 | 398 |
|-----|-----|-----|-----|

| 253-55 | 253-165 |
|--------|--------|

(B) REGN10987  
REGN10933  
AZD1061  
AZD8895

Regeneron mAbs

AstraZeneca mAbs

(legend on next page)
The FRNT50 titers for mAbs 55, 165, 253, and 318 were also relative to the epithopes are not perturbed by the K417N, E484K, and N501Y mutations. Antibodies 55, 165, and 253 are related to each other, and we have previously shown that combining the LCs of 55 or 165 with the HC of 253 leads to a >1 log increase in neutralization. mAb 222 was not the only antibody to show resilience to B.1.351. Antibodies resistant to K417N, E484K, and N501Y mutations have been previously reported (Supasa et al., 2021). Individual FRNT50 values are shown in Table S3.

**Antibodies resistant to K417N, E484K, and N501Y**

mAb 222 was not the only antibody to show resilience to B.1.351. The FRNT50 titers for mAbs 55, 165, 253, and 318 were also relatively equal between Victoria and B.1.351, indicating that their epitopes are not perturbed by the K417N, E484K, and N501Y mutations. Antibodies 55, 165, and 253 are related to each other, and we have previously shown that combining the LCs of 55 or 165 with the HC of 253 leads to a >1 log increase in neutralization titers (Dejnirattisai et al., 2021). The chimeras 253H/55L and 253H/165L can both neutralize B.1.351, with FRNT50 titers of 9 and 13 ng/mL, respectively. Structures of 253 and these chimera Fabs with either RBD or spike show that they bind almost identically to the same epitope and do not contact any of the three mutation site residues, correlating well with the neutralization and BLI binding data (Figure 5C).

### DISCUSSION

Coronaviruses are positive-stranded RNA viruses, and although the RNA polymerase possesses limited proofreading capacity, they are intrinsically prone to mutational change. The evolution of SARS-CoV-2 from a likely single-point zoonotic introduction in Wuhan in November or December 2019 has been widely anticipated and indeed led to the establishment of viral sequence surveillance such as COG-UK in the UK. Similar surveillance efforts have been started in a number of countries, but globally coverage is insufficient, with large at-risk populations with little or no capacity.

The recent emergence of three strains of SARS-CoV-2, B.1.1.7, B1.351, and P.1, which may impart increased transmissibility, has occurred independently in the UK, South Africa, and Brazil, where they have rapidly become dominant strains and are now spreading globally. While the sequences are markedly different, each containing 9–12 changes, there are two common themes. The first theme involves the ACE2 interaction surface of the RBD: all share the N501Y mutation, while B.1.351 and P.1 share E484K and N501Y and both B.1.351 and P.1 have changes at 417, 417T in P.1 and 417N in B.1.351. The second theme is deletions in the NTD: 69–70 and 144 in B.1.1.7 and 242–244 in B.1.351, both of which will disrupt the binding sites of neutralizing anti-NTD antibodies, as shown here by the failure of neutralization of anti-NTD mAb 159. Although P.1 does not possess NTD deletions, it is studded with point mutations in this region that may confer similar functional properties. Despite the changes in B.1.351, residual neutralizing capacity is present in many convalescent and vaccine sera, with some individuals showing minimal reduction of titers relative to the Victoria strain.

Although the majority of potent mAbs suffered substantial reduction or knockout of activity, a number were able to potentially neutralize B.1.351, including 222, 318, 253/55, and 353/165, the AstraZeneca pair AZD1061 and AZD889, and Regeneron REGN10987, which does not contact any of the mutation sites, whereas REGN10933 contacts both 417 and 484 and binding is abrogated. By analysis of known structures of Fab/RBD complexes, we are able to rationalize the effects on all potent binders to the Victoria virus in terms of interactions with the three mutated residues in the RBD.

How much further mutation in the RBD these antibodies will be able to withstand is not known, but the use of cocktails of antibodies to hedge against viral variants occurring either during a single infection, or at a population level, appears to be a sound strategy. However, it must be recognized that the use of mAb therapy or prophylaxis, particularly for extended periods in chronically infected immunocompromised individuals, is likely to drive the emergence of resistance mutations.

The widespread emergence of variant strains, particularly containing the E484K mutation, may make it prudent to develop mAbs to target the 484K change. It may also be possible to re-engineer existing candidate therapeutic antibodies; an example of how subtle changes can confer resilience is shown by mAb 222, which possesses the IGHV3-53 V-region. While all other IGHV3-53 antibodies are severely compromised in binding B.1.351, a slight change in the length of the HC CDR3 and a suitable choice of LC enable mAb 222 to maintain potency against B.1.1.7 and B.1.351.

In *in vitro* evolution experiments have recently been reported (Starr et al., 2020) in which live virus has been induced to evolve in the face of immune pressure from either mAbs or polyclonal serum. Interestingly, repeated use of plasma therapy in an immunocompromised individual led to the transient emergence of the deletion of F140 and the creation of a new N-linked glycosylation sequon in the NTD together with the E484K RBD mutation (Andreano et al., 2020).

Alternatively, yeast display of libraries of RBD mutants has been used to select variants for escape from binding to immune serum or alternatively for increased affinity of binding to the ACE2 receptor (Zahradnik et al., 2021). Of great interest is that all of these approaches have led to the identification of a common set of mutations found in the variant viruses that are now circulating. Principal among these are N501Y found in all B.1.1.7, B.1.351, and P.1 lineages and E484K found in B.1.351 and P.1. These mutations increase the affinity of the RBD for ACE2 2.7-fold for B.1.1.7 (Supasa et al., 2021) and 19-fold for B.1.351, which is compatible with the observation that viruses carrying the E484K and N501Y mutations likely have increased transmissibility.

Here, we demonstrate that the B.1.351 CoV-2 strain is much more difficult to neutralize than parental strains; 14 of 20 of a panel of mAbs are seriously compromised or neutralization is completely knocked out. On convalescent serum, the
Neutralization titers are reduced 13.3-fold for B.1.351 compared with the Victoria strain, with 14 of 34 failing to reach an NT50 at a 1:20 dilution and a number showing almost complete knockdown of activity. It remains to be determined whether this reflects a focusing of the immune response in these individuals, as has been seen, for instance, for the picornavirus enterovirus-71 (Huang et al., 2020). Neutralization titers for the Oxford-AstraZeneca and Pfizer vaccines were similarly reduced with B.1.351 by 9-fold and 7.6-fold, respectively. For the Oxford-AstraZeneca vaccine compared with the Pfizer vaccine, more sera failed to reach FRNT50 at 1:20 dilution, and since the reduction in FRNT50 titers between the two vaccines was quite similar, this effect was due to the 3.6-fold lower starting titers for the Oxford-AstraZeneca vaccine versus the Pfizer-BionTech vaccine. However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (~76 and 89%, respectively) (https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/961287/Greenbook_chapter_14a_v7_12Feb2021.pdf; Baden et al., 2021; Polack et al., 2020; Voysey et al., 2021b)), implying neutralizing antibody titers required for this level of protection are modest.

Very recent data suggest that the Novavax vaccine, which achieved 95.6% efficacy against previous SARS-CoV-2 strains and 85.6% against B.1.1.7 in the UK, had reduced efficacy of 60% in South Africa, where 92.6% of infections are estimated to have been B.1.351 (https://www.novavax.com/sites/default/files/2021-02/20210202-NYAS-Novavax-Final.pdf). Furthermore, data from the Novavax trial in South Africa indicate that approximately one-third of the study participants were seropositive at enrollment; however, in the placebo arm of the study, there was...
no difference in the rate of infection in seronegative versus seropositive volunteers (3.9 versus 3.9%), implying a lack of protection of previous SARS-CoV-2 exposure to infection with B.1.351. The Janssen single-dose COVID-19 vaccine showed 72% efficacy at preventing moderate and severe disease, which was reduced to 57% in South Africa. Finally, a recent report from South Africa on a small sample size suggests substantial loss of efficacy for the Oxford-AstraZeneca vaccine against B.1.351 infection (10.6% efficacy against mild-to-moderate disease [Madhi et al., 2021]). There are no reports yet of the efficacy of the Pfizer-BioNTech vaccine against B.1.351; however, the neutralization titers reported here suggest that a degree of efficacy will be retained. Overall, these results suggest that previous infection or vaccination with ancestral strains of SARS-CoV-2 may not provide adequate protection against B.1.351.

What is driving the evolution of B.1.351 is difficult to disentangle. On the one hand, we show here an ~20-fold increase in affinity for ACE2 compared with Wuhan RBD, which may influence transmissibility. On the other hand, the substantial antibody immune escape by B.1.351 is likely playing a role in countries such as South Africa, where the rates of previous infection are relatively high (estimate >30%). The trade-off of increased ACE2 affinity and transmissibility against immune escape is likely complex; as population immunity increases due to vaccination and natural infection, the evolutionary pressure for viral variants to be selected ratchets up. The ability to generate ultra-high-affinity RBD variants for ACE2 in the sub-picomolar range by in vitro evolution (Zahradnik et al., 2021), a higher affinity than almost all mAbs described to date, is a cause for concern. Whether such viruses with extreme ACE2/RBD affinity are viable is clearly unknown, and extreme caution should be exercised as to whether this scenario should ever be tested using live viruses.

In summary, the recent emergence of multiple variant strains of SARS-CoV-2 has disrupted confidence around whether the current generation of vaccines will provide long-term protection against infection. The possibility of escape from natural and vaccine-induced immunity has prompted a rush to understand the consequences of these changes and spurred a push to develop new vaccine constructs tailored to the variants, particularly incorporating the E484K mutation. How previously infected or vaccinated individuals respond to these new variant vaccines will be the subject of intense study over the coming months, as there is a general reckoning that the current problem is not over. However, even if antibody responses to the new variants are not able to prevent infection, they may moderate severity. In addition, T cell responses to spike may not be disrupted by the mutational changes and be able to limit spread to the lower respiratory tract and prevent severe disease.

Intensive surveillance systems need to be implemented to monitor for the emergence of new variants and, in particular, to be targeted at searching for breakthrough infections in...
vaccinees. Work on second and even third generation vaccines to target variant viruses and more broadly to develop immunogens to targets less reliant on the ACE2-RBD interaction surface are deserving of further study.

**Limitations of the study**
The vaccine and convalescent samples used in the neutralization studies in this report were taken early and titers may rise further; conversely, it is also likely that titers will wane with time and that protection from B.1.351 afforded by antibody responses to early SARS-CoV-2 strains may reduce. It will also be important to know how serum from individuals infected with B.1.351 is able to neutralize early Wuhan-related strains as well as the recently reported variants B.1.1.7 and P.1. Furthermore, since E484K appears to be such an important mutation with respect to antibody binding and neutralization, future studies may seek to define mAbs from individuals infected with E484K viruses to provide protection from these virus strains that are being pressured to emerge, we believe mainly through increased fitness imparted by the higher affinity of RBD for ACE2. Finally, it will be important to determine whether vaccination or natural infection with early strains of SARS-CoV-2 still affords protection from severe disease and hospitalization, the most important metrics of vaccine success.

**STAR METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead contact
  - Materials availability
  - Data and code availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Viral stocks
  - Bacterial Strains and Cell Culture
  - Participants
  - Sera from Pfizer vaccinees
  - AstraZeneca-Oxford vaccine study procedures and sample processing
- **METHOD DETAILS**
  - COG-UK Sequence Analysis
  - Focus Reduction Neutralization Assay (FRNT)
  - Cloning of native RBD, ACE2 and RBD K417N, E484K, N501Y
  - Protein production
  - Bio-Layer Interferometry
- **QUANTITATIVE AND STATISTICAL ANALYSIS**

**SUPPLEMENTAL INFORMATION**

Supplemental information can be found online at https://doi.org/10.1016/j.cell.2021.02.037.

**ACKNOWLEDGMENTS**

This work was supported by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant 2018-i2M-2-002) to D.J.S. and G.R.S. H.M.E.D. and J.R. are supported by the Wellcome Trust (101122/2/13/Z), Y.Z. by Cancer Research UK (C375/A17721), and D.J.S. and E.E.F. by the UK Medical Research Council (MR/N00065X/1). D.J.S. is a Jenner Investigator. We are grateful for a Fast grant from Fast Grants, Mercatus Center, to support the isolation of human mAbs to SARS-CoV-2 and Schmidt Futures for support of this work. G.R.S. is also supported as a Wellcome Trust Senior Investigator grant 095541/A/11/2. This is a contribution from the UK Instruct-ERIC Centre. The Wellcome Centre for Human Genetics is supported by the Wellcome Trust grant 090532/Z/08/Z. Virus used for the neutralization assays was a gift from Julian Druce, Doherty Centre, Melbourne, Australia, Chance Knight, Emily Chipolin, Ross Fothergill, and Liz Penn contributed to assays. We acknowledge Diamond Light Source for time on Beamline I03 under proposal i27009 for COVID-19 Rapid Access. Huge thanks to the teams, especially at the Diamond Light Source and Department of Structural Biology, Oxford University, who have enabled work to continue during the pandemic. The computational aspects of this research were supported by the Wellcome Trust Core Award Grant 203141/2/16/2 and the NIHR Oxford BRC. The Oxford Vaccine work was supported by UK Research and Innovation, Coalition for Epidemic Preparedness Innovations, National Institute for Health Research (NIHR), NIHR Oxford Biomedical Research Centre, and Thames Valley and South Midland’s NIHR Clinical Research Network. We thank the Oxford Protective T-cell Immunology for COVID-19 (OPTIC) Clinical team for participant sample collection and the Oxford Immunology Network COVID-19 Response T cell Consortium for laboratory support. We acknowledge the rapid sharing of the variant B.1.351, which was isolated by scientists within the National Infection Service at PHE Porton Down. This work was supported by the UK Department of Health and Social Care as part of the PiTCH (Protective Immunity from T cells to COVID-19 in Health Workers) Consortium, the UK Coronavirus Immunology Consortium (UK-CIC), and the Huo Family Foundation. E.B. and P.K. are NIHR Senior Investigators, and P.K. is funded by WT109965MA and NIH(U191082360), J.C.K is a Wellcome Investigator (WT204969/Z/16/2) and is supported by NIHR Oxford Biomedical Research Centre and CIFMS. D.S. is an NIHR Academic Clinical Fellow, and S.F.L. is funded as a Wellcome Trust clinical research fellow. The views expressed in this article are those of the authors and not necessarily those of the National Health Service (NHS), the Department of Health and Social Care (DHSC), the NIHR, the Medical Research Council (MRC), or Public Health, England.

**AUTHOR CONTRIBUTIONS**

D.Z. performed BLI interaction analyses. J.R., E.E.F., H.M.E.D., and D.J.S. analyzed the structural results. G.R.S., J.M., P.S., Y.Z., D.Z., G.C.P., and C.L. prepared the spike constructs, RBDS, ACE2, and antibodies. W.D. performed neutralization assays with B.W., F.R.N., A.T., J.S.-C., and C.L.-C. B.H., N.C., K.B., S.C., N.B., I.S.H., K.G., N.G., and A.S. provided B.1.351 virus and contributed to experimental design. D.C. and W.J. provided materials. H.M.G. wrote mabscape and performed mapping and cluster analysis, including sequence analyses. A.J.M., S.F.L., E.B., S.J.D., C.D., R.L., T.D., A.J.P., J.C.K., P.K., M.W.C., T.L., S.B., A.F., M.B., S.B.-R., E.C., and S.G. assisted with patient samples and vaccine trials. E.B., M.C., S.J.D., P.K., and D.S. conceived the study of vaccinated healthcare workers and oversaw the OPTIC Healthcare Worker study and sample collection/processing. G.R.S. and D.J.S. wrote the initial manuscript draft with other authors providing editorial comments. All authors read and approved the manuscript.

**DECLARATION OF INTERESTS**

G.R.S. sits on the GSK Vaccines Scientific Advisory Board. Oxford University holds intellectual property related to the Oxford-AstraZeneca vaccine. A.J.P. is Chair of UK Department Health and Social Care’s (DHSC) Joint Committee on Vaccination & Immunisation (JCVI), but does not participate in the JCVI COVID-19 committee, and is a member of the WHO’s SAGE. The views expressed in this article do not necessarily represent the views of DHSC, JCVI, or WHO. The University of Oxford has entered into a partnership with AstraZeneca on coronavirus vaccine development. The University of Oxford has protected intellectual property disclosed in this publication.
REFERENCES

Andreato, E., Piccini, G., Licastro, D., Casalino, L., Johnson, N.V., Paciello, I., Monego, S.D., Pantano, E., Manganaro, N., Manenti, A., et al. (2020). SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. bioRxiv. https://doi.org/10.1101/2020.12.28.424451.

Aricesu, A.R., Lu, W., and Jones, E.Y. (2006). A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallographica D Biocystallography 62, 1243–1250.

Baden, L.R., El Sahly, H.M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S.A., Rouphael, N., Creech, C.B., et al.; COVE Study Group (2021). Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 384, 403–416.

Baum, A., Fulton, B.O., Wloga, E., Copin, R., Pascal, K.E., Russo, V., Giordano, S., Lanza, K., Negron, N., Ni, M., et al. (2020). Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 369, 1014–1018.

Calv, L., Druce, J., Roberts, J., Bond, K., Tran, T., Kostekci, R., Yoga, Y., Naughton, W., Tairao, G., Seemann, T., et al. (2020). Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia. Med. J. Aust. 212, 459–462.

Cerutti, G., Guo, Y., Zhou, T., Gorman, J., Lee, M., Rapp, M., Reddem, E.R., Yu, J., Bahna, F., Bimela, J., et al. (2021). Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite. bioRxiv. https://doi.org/10.1101/2021.01.14.426475.

Chi, X., Yan, R., Zhang, J., Zhang, Y., Hao, M., Zhang, Z., Fan, P., Dong, Y., Yang, et al. (2020). A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science 369, 650–655.

Dejnirattisai, W., Zhou, D., Ginn, H.M., Duyvesteyn, H.M.E., Supasa, P., Case, J.B., Zhao, Y., Walter, T.S., Mentzer, A.J., Liu, C., et al. (2021). The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell 184. https://doi.org/10.1016/j.cell.2021.02.032.

Faria, N.R., Claro, I.M., Candido, D., Moyes Franco, L.A., Andrade, P.S., Coletti, T.M., Silva, C.A.M., Sales, F.C., Manuli, E.R., Aguiar, R.S., et al. (2021). Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings - SARS-CoV-2 coronavirus / nCoV-2019 Genomic Epidemiology - Virological. virological.org. https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings-sars-cov-2-coronavirus-ncov-2019-genomic-epidemiology-virological.

Faria, N.R., Claro, I.M., Candido, D., Moyses Franco, L.A., Andrade, P.S., Coletti, T.M., Silva, C.A.M., Sales, F.C., Manuli, E.R., Aguiar, R.S., et al.; C4591001 Clinical Trial Group (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Nat. Commun. 11, 459–462.

Hosmillo, M., Rees-Spear, C., Mlcochova, P., Lumb, I.U., et al.; CITIID-NIHR Rare Diseases North East Translational Research Institute, National Institute of Health Research (NIHR), NHS Confederation (2021). Sixteen site randomised controlled trial of 2019 novel coronavirus (COVID-19) infection reducing interventions in primary care: the SAFER trial. BMJ Open 11, 100651.

Krammer, F. (2020). SARS-CoV-2 vaccines in development. Nature 586, 516–527.

Ku, Z., Xie, X., Davidson, E., Ye, X., Su, H., Menachery, V.D., Li, Y., Yuan, Z., Zhang, X., Muruato, A.E., et al. (2021). Molecular determinants and mechanisms for antibody cocktail preventing SARS-CoV-2 escape. Nat. Commun. 12, 469.

Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origin and receptor binding. Lancet 395, 565–574.

Madhi, S.A., Baillie, V., Cutland, C.L., Vosrey, M., Koen, A.L., Fairlie, L., Pagdayachee, S.D., Dheda, K., Barnabas, S.L., Bharat, Q.E., et al. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccine against the B.1.351 variant in South Africa. medRxiv. https://doi.org/10.1101/2021.02.10.21231427.

McCallum, M., De Marco, A., Lempp, F., Tortorici, M.A., Pinto, D., Walls, A.C., Beltramello, M., Chen, A., Liu, Z., Zatta, F., et al. (2021). N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. bioRxiv. https://doi.org/10.1101/2021.01.14.426475.

Polack, F.P., Thomas, S.J., Kitchin, N., Abasaloi, J., Gurtman, A., Lockhart, S., Perez, J.L., Perez Marc, G., Moreira, E.D., Zerbini, C., et al.; C4591001 Clinical Trial Group (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 383, 2603–2615.

Seemann, T., Lane, C.R., Sherry, N.L., Duchene, S., Goncalves da Silva, A., Caly, L., Salt, M., Ballard, S.A., Horan, K., Schultz, M.B., et al. (2020). Tracking the COVID-19 pandemic in Australia using genomics. Nat. Commun. 11, 4376.

Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Alhara, H., Geng, Q., Auerbach, A., and Li, F. (2020). Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221–224.

Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., Song, T., Bi, X., Han, C., Wu, L., et al. (2020). A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120–124.

Starr, T.N., Greaney, A.J., Hilton, S.K., Ellis, D., Crawford, K.H.D., Dingens, A.S., Navarro, M.J., Bowen, J.E., Tortorici, M.A., Walls, A.C., et al. (2020). Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. Cell 182, 1295–1310.e20.

Supasa, P., Zhou, D., Dejnirattisai, W., Chang, L., Mentzer, A.J., Ginn, H.M., Zhao, Y., Duyvesteyn, H.M.E., Nuttall, R., and Tuenphakophon, A. (2021). Reduced neutralization of SARS-CoV-2 B.1.1.7 variant from naturally acquired and vaccine induced antibody immunity. SSRN.

Tatusov, R.L., Galperin, M.Y., Natale, D.A., and Koonin, E.V. (2000). The COG database: a tool for genome-scale analysis of protein functions and evolution. Nucleic Acids Res. 28, 33–36.

Teggally, H., Wilkinson, E., Lessells, R.J., Giandhari, J., Pillay, S., Msomi, N., Miliana, K., Bhaman, J.N., von Gottberg, A., Walaza, S., et al. (2021). Sixteen novel lineages of SARS-CoV-2 in South Africa. Nat. Med. https://doi.org/10.1038/s41588-021-01255-3.

Vosrey, M., Clemens, S.A.C., Madhi, S.A., Weckx, L.Y., Folegatti, P.M., Aley, P.K., Angus, B., Baillie, V.L., Barnabas, S.L., Bharat, Q.E., et al.; Oxford COVID Vaccine Trial Group (2021a). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99–111.

Vosrey, M., Clemens, S.A.C., Madhi, S.A., Weckx, L.Y., Folegatti, P.M., Aley, P.K., Angus, B., Baillie, V.L., Barnabas, S.L., Bharat, Q.E., et al. (2021b). Single dose administration, and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine. SSRN. https://www.ssrn.com/abstract=3777268.

Wajnberg, A., Amanat, F., Fipo, A., Altmann, D.R., Bailey, M.J., Mansour, M., McMahan, M., Meade, P., Mendu, D.R., Mueller, K., et al. (2020). Robust
neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 370, 1227–1230.
Yang, L., Liu, W., Yu, X., Wu, M., Reichert, J.M., and Ho, M. (2020). COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19. Antib. Ther. 3, 205–212.
Yuan, M., Liu, H., Wu, N.C., Lee, C.D., Zhu, X., Zhao, F., Huang, D., Yu, W., Hua, Y., Tien, H., et al. (2020). Structural basis of a shared antibody response to SARS-CoV-2. Science 369, 1119–1123.

Zahradník, J., Marciano, S., Shemesh, M., Zoler, E., Chiaravalli, J., Meyer, B., Dym, O., Elad, N., and Schreiber, G. (2021). SARS-CoV-2 RBD in vitro evolution follows contagious mutation spread, yet generates an able infection inhibitor. bioRxiv, 2021.01.06.425392.
Zhou, D., Duyvesteyn, H.M.E., Chen, C.P., Huang, C.G., Chen, T.H., Shih, S.R., Lin, Y.C., Cheng, C.Y., Cheng, S.H., Huang, Y.C., et al. (2020). Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nat Struct Mol Biol 27, 950–958.
## STAR METHODS

### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| Fab                 | (Dejnirattisai et al., 2021) | N/A        |
| IgG                 | (Dejnirattisai et al., 2021) | N/A        |
| Human anti-NP (mAb 206) | (Dejnirattisai et al., 2021) | N/A        |
| Regeneron mAbs      | AstraZeneca | Cat#REGN10933, and REGN10987 |
| AstraZeneca mAbs    | AstraZeneca | Cat#AZD1061, AZD8895 |
| Anti-Human IgG (Fc specific)-Peroxidase | Sigma | Cat#A0170 RRID: AB_257868 |
| **Bacterial and virus strains** |        |            |
| SARS-CoV-2 (Australia/VIC01/2020) | Caly et al., 2020 | N/A |
| SARS-CoV-2/B.1.1.7 | Public Health England | N/A |
| DH5a bacteria       | In Vitrogen | N/A |
| **Biological samples** |        |            |
| Serum from Pfizer-vaccinated individuals | University of Oxford | N/A |
| Serum from AstraZeneca-Oxford-vaccinated individuals | University of Oxford | N/A |
| Plasma from SARS-CoV-2 patients | John Radcliffe Hospital in Oxford UK | N/A |
| **Chemicals, peptides, and recombinant proteins** |        |            |
| His-tagged SARS-CoV-2 RBD | This paper | N/A |
| His-tagged SARS-CoV-2 RBD K417N, E484K, N501Y | This paper | N/A |
| His-tagged human ACE2 | This paper | N/A |
| Human ACE2-hIgG1Fc | This paper | N/A |
| Phosphate buffered saline tablets | Sigma-Aldrich | Cat#P4417 |
| Dulbecco’s Modified Eagle Medium, high glucose | Sigma-Aldrich | Cat#D5796 |
| Dulbecco’s Modified Eagle Medium, low glucose | Sigma-Aldrich | Cat#D6046 |
| FreeStyle 293 Expression Medium | GIBCO | Cat#12338018 |
| L-Glutamine–Penicillin–Streptomycin solution | Sigma-Aldrich | Cat#G1146 |
| Fetal Bovine Serum | GIBCO | Cat#12676029 |
| Polyethyleneimine, branched | Sigma-Aldrich | Cat#408727 |
| Carboxymethyl cellulose | Sigma | Cat#C4888 |
| Strep-Tactin®XT | IBA Lifesciences | Cat#2-1206-025 |
| HEPES | Melford | Cat#34587-39108 |
| Sodium Chloride | Honeywell | Cat#SZBF3340H |
| LB broth | Fisher Scientific UK | Cat#51577-51656 |
| Mem Neaa (100X) | GIBCO | Cat#2203945 |
| Trypsin-EDTA | GIBCO | Cat#2259288 |
| L-Glutamine 200 mM (100X) | GIBCO | Cat#2036885 |
| SYPROorange (5000X in DMSO) | Thermo | Cat#S6651 |
| Isopropyl [l-d-1-thiogalactopyranoside | Meridian Bioscience | Cat#BIO-37036 |
| Kanamycin | Melford | Cat#K22000 |

(Continued on next page)
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Lysozyme           | Sigma-Aldrich | Cat#L6876  |
| Tris-base          | Melford   | Cat#T60040 |
| Imidazole           | Sigma-Aldrich | Cat#56750  |
| Triton X-100       | Sigma-Aldrich | Cat#8787   |
| Turbonuclease       | Sigma-Aldrich | Cat#T4330  |
| RNase A             | Qiagen    | Cat#158922 |
| NaCl                | Sigma-Aldrich | Cat#S9888  |
| MgSO4               | Sigma-Aldrich | Cat#746452 |
| Na2HPO4             | Melford   | Cat#S23100 |
| NaH2PO4             | Melford   | Cat#S23185 |

**Experimental models: cell lines**

| Model               | Source   | Cat# or RRID |
|---------------------|----------|--------------|
| HEK293S GnTI- cells | ATCC     | CRL-3022 RRID: CVCL_A785 |
| HEK293 cells        | ATCC     | CRL-3216 RRID: CVCL_0063 |
| Expi293F Cells      | Gibco    | A14527       |
| Hamster: ExpiCHO cells | Thermo Fisher | A29133   |
| Vero cells          | ATCC     | CCL-81 RRID: CVCL_0059 |

**Recombinant DNA**

| Vector              | Origin                           | Cat# or RRID |
|---------------------|----------------------------------|--------------|
| pHLsec              | (Aricescu et al., 2006)          | N/A          |
| pNeo                | (Aricescu et al., 2006)          | N/A          |
| pOPEN-ET            | (Nettleship et al., 2008)        | N/A          |
| human ACE2 cDNA     | Sourcebiosciences                | 5297380      |
| Vector: human IgG1 heavy chain | German Cancer Research Center, Heidelberg, Germany (H. Wardemann) | N/A |
| Vector: human lambda light chain | German Cancer Research Center, Heidelberg, Germany (H. Wardemann) | N/A |
| Vector: human kappa light chain | German Cancer Research Center, Heidelberg, Germany (H. Wardemann) | N/A |
| Vector: Human Fab   | University of Oxford             | N/A          |
| Vector: Human scFv  | University of Oxford, NDM (G. Screaton) | N/A |

**Software and algorithms**

| Software            | Source                           | RRID  |
|---------------------|----------------------------------|-------|
| PyMOL               | Schrodinger                      | [RRID](SCR_000305) |
| Data Acquisition Software 11.1.0.11 | Fortebio | [RRID](SCR_002798) |
| Data Analysis Software HT 11.1.0.25 | Fortebio | [RRID](SCR_019096) |
| Prism 8.0           | GraphPad                         | [RRID](SCR_002798) |
| IBM SPSS Software 26 | IBM                              | [RRID](SCR_019096) |
| mabscape            | This paper                       | [RRID](SCR_002798) |

**Other**

| Resource            | Source           | Cat#          |
|---------------------|------------------|---------------|
| TALON® Superflow Metal Affinity Resin | Clontech         | 635688        |
| HiLoad® 16/600 Superdex® 200 pg | Cytiva           | 28-9893-35    |
| Superdex 200 increase 10/300 GL column | Cytiva           | 28990944      |
| HisTrap HP 5-ml column | Cytiva           | 17524802      |
| HiTrap Heparin HT 5-ml column | Cytiva           | 17040703      |

(Continued on next page)
RESOURCE AVAILABILITY

Lead contact
Resources, reagents and further information requirement should be forwarded to and will be responded by the Lead Contact, David I Stuart (dave@strubi.ox.ac.uk).

Materials availability
Reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

Data and code availability
Mabscape is available from https://github.com/helenginn/mabscape, https://snapcraft.io/mabscape. The data that support the findings of this study are available from the corresponding authors on request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Viral stocks
SARS-CoV-2/human/AUS/VIC01/2020 (Caly et al., 2020) and SARS-CoV-2/B.1.351, provided by Public Health England, were both grown in Vero (ATCC CCL-81) cells. Cells were infected with the SARS-CoV-2 virus using an MOI of 0.0001. Virus containing supernatant was harvested at 80% CPE and spun at 2000 rpm at 4°C before storage at –80°C. Viral titers were determined by a focus-forming assay on Vero cells. Both Victoria passage 5 and B.1.351 passage 4 stocks were sequenced to verify that they contained the expected spike protein sequence and no changes to the furin cleavage sites. The B1.351 virus used in these studies contained the following mutations: D80A, D215G, L242-244 deleted, K417N, E484K, N501Y, D614G, A701V.

Bacterial Strains and Cell Culture
Vero (ATCC CCL-81) cells were cultured at 37°C in Dulbecco’s Modified Eagle medium (DMEM) high glucose (Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS), 2 mM GlutaMAX (GIBCO, 35050061) and 100 U/ml of penicillin–streptomycin. Human mAbs were expressed in HEK293T cells cultured in UltraDOMA PF Protein-free Medium (Cat# 12-727F, LONZA) at 37°C with 5% CO2. E.coli DH5α bacteria were used for transformation of plasmid pNEO-RBD K417N, E484K, N501Y. A single colony was picked and cultured in LB broth with 50 µg mL⁻¹ Kanamycin at 37°C at 200 rpm in a shaker overnight. HEK293T (ATCC CRL-11268) cells were cultured in DMEM high glucose (Sigma-Aldrich) supplemented with 10% FBS, 1% 100X Mem Neaa (GIBCO) and 1% 100X L-Glutamine (GIBCO) at 37°C with 5% CO2. To express RBD, RBD K417N, E484K, N501Y and ACE2, HEK293T cells were cultured in DMEM high glucose (Sigma) supplemented with 2% FBS, 1% 100X Mem Neaa and 1% 100X L-Glutamine at 37°C for transfection.

Participants
Participants were recruited through three studies: Sepsis Immunomics [Oxford REC C, reference:19/SC/0296]), ISARIC/WHO Clinical Characterization Protocol for Severe Emerging Infections [Oxford REC C, reference 13/SC/0149] and the Gastro-intestinal illness in Oxford: COVID sub study [Sheffield REC, reference: 16/YH/0247]. Diagnosis was confirmed through reporting of symptoms consistent with COVID-19 and a test positive for SARS-CoV-2 using reverse transcriptase polymerase chain reaction (RT-PCR) from an upper respiratory tract (nose/throat) swab tested in accredited laboratories. A blood sample was taken following consent at least 14 days after symptom onset. Clinical information including severity of disease (mild, severe or critical infection according to recommendations from the World Health Organization) and times between symptom onset and sampling and age of participant was captured for all individuals at the time of sampling.

Sera from Pfizer vaccinees
Pfizer vaccine serum was obtained 7-17 days following the second dose of vaccine which was administered 3 weeks after the first dose (participants were to the best of their knowledge seronegative at entry).
The study was approved by the Oxford Translational Gastrointestinal Unit GI Biobank Study 16/YH/0247 [research ethics committee (REC) at Yorkshire & The Humber – Sheffield]. The study was conducted according to the principles of the Declaration of Helsinki (https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/) and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. Written informed consent was obtained for all patients enrolled in the study. Vaccinees were Health Care Workers, based at Oxford University Hospitals NHS Foundation Trust, not known to have prior infection with SARS-CoV-2. Each received two doses of COVID-19 mRNA Vaccine BNT162b2, 30 μg, administered intramuscularly after dilution as a series of two doses (0.3 mL each) 18-28 days apart. The mean age of vaccines was 43 years (range 25-63), 11 male and 14 female.

AstraZeneca-Oxford vaccine study procedures and sample processing
Full details of the randomized controlled trial of ChAdOx1 nCoV-19 (AZD1222), were previously published (PMID: 33220855/PMD); 32702298). These studies were registered at ISRCTN (15281137 and 89951424) and ClinicalTrials.gov (NCT04324606 and NCT04400838). Written informed consent was obtained from all participants, and the trial is being done in accordance with the principles of the Declaration of Helsinki (2008) and Good Clinical Practice. The studies were sponsored by the University of Oxford (Oxford, UK) and approval obtained from a national ethics committee (South Central Berkshire Research Ethics Committee, reference 20/SC/0145 and 20/SC/0179) and a regulatory agency in the United Kingdom (the Medicines and Healthcare Products Regulatory Agency). An independent DSMB reviewed all interim safety reports. A copy of the protocols was included in previous publications (PMID: 33220855/PMD: 32702298).

Data from vaccinated volunteers who received two vaccinations are included in this paper. Vaccine doses were either 5 × 10^10 viral particles (standard dose; SD/SD cohort n = 21) or half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort n = 4). The interval between first and second dose was in the range of 8-14 weeks. Blood samples were collected and serum separated on the day of vaccination and on pre-specified days after vaccination e.g., 14 and 28 days after boost.

METHOD DETAILS

COG-UK Sequence Analysis
COG-UK sequences from the 2nd February 2021 (Tatusov et al., 2000), and GISAID sequences (https://www.gisaid.org/) from South Africa from 30th January 2021 were downloaded and the protein sequence for the Spike protein was obtained after nucleotide 21000, followed by sequence alignment and recognition of mutations. The B.1.351 variant was filtered using selection criteria 501Y and Δ242. The B.1.1.7 variant was filtered using selection criteria 501Y and Δ69. The structural locations of mutations were modeled as red (single point mutations), black (deletions) or blue (additions) on the Spike structure with the size proportional to the logarithm of the incidence, and those mutations over 5% incidence in the population were explicitly labeled.

Focus Reduction Neutralization Assay (FRNT)
The neutralization potential of Ab was measured using a Focus Reduction Neutralization Test (FRNT), where the reduction in the number of the infected foci is compared to a negative control well without antibody. Briefly, serially diluted Ab or plasma was mixed with SARS-CoV-2 strain Victoria or B.1.351 and incubated for 1 hr at 37°C. The mixtures were then transferred to 96-well, cell culture-treated, flat-bottom microplates containing confluent Vero cell monolayers in duplicate and incubated for a further 2 hr followed by the addition of 1.5% semi-solid carboxymethyl cellulose (CMC) overlay medium to each well to limit virus diffusion. A focus forming assay was then performed by staining Vero cells with human anti-NP mAb (mAb206) followed by peroxidase-conjugated goat anti-human IgG (A0170; Sigma). Finally, the foci (infected cells) approximately 100 per well in the absence of antibodies, were visualized by adding TrueBlue Peroxidase Substrate. Virus-infected cell foci were counted on the classic AID ELiSpot reader using AID ELiSpot software. The percentage of focus reduction was calculated and IC_{50} was determined using the probit program from the SPSS package.

Cloning of native RBD, ACE2 and RBD K417N, E484K, N501Y
The constructs of native RBD and ACE2 are the same as in (Zhou et al., 2020). To clone RBD K417N, E484K, N501Y, a construct of RBD with the mutation N501Y (Supasa et al., 2021) was used as the template and four primers of RBD (K417N Forward primer 5'-CAGGGCAGCACCAGCATGCGCAGACTACATTAC-3', K417N reverse primer 5'-GTAATTGTAGTGCAGATATGCGGCT-3', E484K Forward primer 5'-CACAGTGAATGAGGCGTTCAATTGCTAC-3' and E484K reverse primer 5'-GTAATTGTAGTGCAGATATGCGGCT-3') and two primers of pNEO vector (Forward primer 5'-CAGGTTGCTGGCAACCGTG-3' and reverse primer 5'-GTAATTGTAGTGCAGATATGCGGCT-3') were used to do PCR. Amplified DNA fragments were digested with restriction enzymes ApaI and KpnI and then ligated with digested pNEO vector. This construct encodes exactly the same protein as native RBD except the K417N, E484K and N501Y mutations, as confirmed by sequencing.
Protein production
Protein production was as described in (Zhou et al., 2020). Briefly, plasmids encoding proteins were transiently expressed in HEK293T (ATCC CRL-11268) cells. The conditioned medium was dialysed and purified with a 5 mL HisTrap nickel column (GE Healthcare) and further polished using a Superdex 75 HiLoad 16/60 gel filtration column (GE Healthcare).

Bio-Layer Interferometry
BLI experiments were run on an Octet Red 96e machine (Fortebio). To measure the binding affinities of monoclonal antibodies and ACE2 with native RBD and RBD K417N, E484K, N501Y, each RBD was immobilized onto an AR2G biosensor (Fortebio). Monoclonal antibodies (Dejnirattisai et al., 2021) were used as analytes or serial dilutions of ACE2 were used as analytes. All experiments were run at 30°C. Data were recorded using software Data Acquisition 11.1 (Fortebio) and Data Analysis HT 11.1 (Fortebio) with a 1:1 fitting model used for the analysis.

QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses are reported in the results and figure legends. Neutralization was measured by FRNT. The percentage of focus reduction was calculated and IC_{50} was determined using the probit program from the SPSS package. The Wilcoxon matched-pairs signed rank test was used for the analysis and two-tailed P values were calculated and geometric mean values. BLI data were analyzed using Data Analysis HT 11.1 (Fortebio) with a 1:1 fitting model.
Figure S1. Neutralization of Victoria and B.1.351 by serum collected before vaccination, related to Figure 3
Neutralization for Victoria and B.1.351 strains by 50 sera taken at day zero before the first dose of AstraZeneca vaccine. All sera were assayed in three-fold dilutions at 1:20 and 1:60 for the final dilutions.